surpass cvot tirzepatide SURPASS-CVOT shows delivers comparable cardiovascular safety to dulaglutide in patients with type 2 diabetes and established ASCVD, reinforcing the shift toward therapies that optimize whole cardiometabolic systems. As outcome datasets grow AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide
Pay in 4 interest-free payments of $5.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7

























![Delibird (38/149) (League Promo 1st Place) [Black & White: Boundaries Crossed] 10](https://cdn.shopify.com/s/files/1/0617/9821/9946/products/3233cbdb-32d6-4100-b605-7c802d125d0b_a4eedfdd-bdbf-43fd-a3f1-f94b8a0fefb9.jpg?v=1696314658)



